Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 14/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 14/20 | 0.53 |
| ▸ | PRKDC | P78527 | 14/20 | 0.53 |
| ▸ | PIK3CD | O00329 | 13/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.53 |
| ▸ | ABL1 | P00519 | 11/20 | 0.52 |
| ▸ | EGFR | P00533 | 11/20 | 0.52 |
| ▸ | HCK | P08631 | 11/20 | 0.52 |
| ▸ | SRC | P12931 | 11/20 | 0.52 |
| ▸ | MTOR | P42345 | 11/20 | 0.52 |
| ▸ | EPHB4 | P54760 | 11/20 | 0.52 |
| ▸ | KDR | P35968 | 10/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.51 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.48 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.48 |
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31165915 | 1.00 | PIK3CB (0.53) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL31165921 | 0.84 | PIK3CD (0.53) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL21439870 | 0.84 | PIK3CD (0.53) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL16285724 | 0.81 | NUDT14 (0.70) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL12282 | 0.81 | PIK3CD (0.59) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL130622 | 0.78 | PIK3CB (0.58) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL30782445 | 0.77 | NUDT14 (0.69) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL12366 | 0.77 | NUDT14 (0.69) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL30513345 | 0.77 | PIK3CD (0.55) | PIK3CBPIK3CGPRKDCPIK3CDPIK3CA | |
| SCHEMBL20351494 | 0.77 | EIF2AK3 (0.52) | SRCRIPK1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774797-B1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2025-11-19 | — | — | EP | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | MERCK PATENT GMBH (DE) | 2024-01-16 | — | — | US | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2021-06-03 | — | — | US | disclosed |
| EP-3774797-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | Merck Patent GmbH (DE) | 2021-02-17 | — | — | EP | disclosed |
| CN-112236429-A | Heteroaryl compounds as type II IRAK inhibitors and uses thereof | 默克专利有限公司 | 2021-01-15 | — | — | CN | disclosed |
| WO-2019192962-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019192962-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES HEREOF | MERCK PATENT GMBH (DE) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163487-A1 | HETEROARYL COMPOUNDS AS TYPE II IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PIK3CB 119/4885PIK3CG 265/4885PRKDC 282/4885 |
| US-11873303-B2 | Substituted pyrazoles as type II IRAK inhibitors | IRAK2, IRAK3, IRAK1 | PIK3CB 200/4885PIK3CG 527/4885PRKDC 629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.